Is Semaglutide Safe for Long-Term Use? What the Research Actually Says

When the STEP trials concluded that semaglutide 2.4 mg once weekly produced roughly 15% body weight reduction in people with obesity — a number that had previously required bariatric surgery to achieve — the medical community took notice. So did millions of men who had spent years cycling through diets and exercise programs with diminishing returns. But the question that followed almost immediately was the one that matters most for anyone committing to a medication indefinitely: is semaglutide actually safe to take long term?

That is not a simple question, and anyone who answers it too quickly in either direction — breathless enthusiasm or reflexive alarm — is probably not reading the same literature. The honest answer is nuanced, grounded in an expanding body of trial data, and increasingly favorable, with some important caveats that every informed man should understand before making a decision.

What the Clinical Evidence Shows About Long-Term Safety

The most authoritative institutional take on semaglutide’s long-term profile comes from the American Gastroenterological Association, whose 2022 clinical practice guideline — published in Gastroenterology and built using the rigorous GRADE framework — concluded that long-term pharmacological therapy is recommended for adults with overweight and obesity who have an inadequate response to lifestyle interventions alone, with semaglutide among the agents assessed as both effective and safe. That is not a casual endorsement. The AGA convened a multidisciplinary panel that combed through the available evidence on multiple anti-obesity medications and came out specifically supporting semaglutide’s use in clinical practice — not as a short-term intervention, but as a long-term treatment strategy.

Reinforcing that position is a 2023 narrative review published in Diabetes, Obesity & Metabolism, which described semaglutide as a novel potent therapy that significantly reduces body weight by approximately 15%, with simultaneous improvement in cardiometabolic risk factors and physical functioning in people with obesity. The review positioned this generation of GLP-1 receptor agonists as genuinely narrowing the gap between behavioral interventions, older pharmacotherapies, and bariatric surgery — a gap that has defined obesity medicine for decades.

The cardiovascular data is particularly compelling for men who carry significant metabolic risk. The SELECT trial, which enrolled over 17,000 adults with obesity and established cardiovascular disease but without diabetes, demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared to placebo. That trial ran for more than three years, providing some of the most extended safety and efficacy data available on the drug in a non-diabetic population. The signal was not just neutral — it was actively protective. For men whose weight has been quietly eroding their heart health for years, that distinction matters enormously.

Common side effects — nausea, vomiting, constipation, and diarrhea — are well-documented and largely concentrated in the dose-escalation phase. They are real, they affect a meaningful percentage of users, and they are the primary reason people discontinue. But they are also typically transient, manageable with slower titration, and not associated with serious organ-level harm in the vast majority of cases. The more serious concerns that receive disproportionate media attention, including pancreatitis and thyroid C-cell tumors, deserve honest assessment rather than dismissal or amplification.

Pancreatitis risk with GLP-1 receptor agonists has been studied extensively, and the current evidence does not establish a causal link with semaglutide at therapeutic doses. Thyroid C-cell tumors have been observed in rodent studies at exposures far exceeding human therapeutic levels, and there is no confirmed signal in human clinical data — though the drug carries a black box warning and remains contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. These are real exclusion criteria that prescribers are obligated to screen for, not theoretical concerns to wave away.

The Muscle Mass Question Men Need to Take Seriously

Here is where the long-term safety conversation gets more complicated, and where the research is evolving rapidly. Weight loss — from any intervention — involves some loss of lean mass alongside fat. The clinical question is how much, and whether it matters enough to change the risk-benefit calculation.

A 2025 review published in Reviews in Endocrine & Metabolic Disorders put specific numbers on this that every man considering long-term semaglutide use should internalize: of weight lost with semaglutide, approximately 45% is from lean mass, while with tirzepatide, it is 25%. The authors were careful to contextualize this — for most patients, they noted, the muscle loss is not a primary clinical concern. But for older men, or those who are already lean and trying to protect hard-earned muscle, 45% of total weight loss coming from lean tissue is a number worth sitting with.

This does not mean semaglutide is unsafe. It means that semaglutide without a deliberate strategy to preserve muscle is an incomplete approach. The same review emphasized that for the full potential of disease modification to be achieved, safe, long-term body composition improvement must be demonstrated — particularly in older populations. That aligns with what exercise scientists and sports medicine clinicians have argued for years: pharmacological intervention and resistance training are not competing strategies. They are complementary ones.

A 2025 narrative review in the International Journal of Obesity further developed this theme, specifically examining anti-obesity medicines in older adults and concluding that lifestyle interventions remain the cornerstone of obesity management in older adults, with emphasis on resistance training for muscle strength and bone mineral density preservation. The authors acknowledged growing evidence that intentional weight loss in older adults with obesity can be effective and safe, but stressed that resistance training is not optional when you are simultaneously reducing caloric intake and losing significant body weight. The anabolic stimulus from lifting is what signals the body to preserve muscle tissue when overall energy balance is negative.

The practical implication for any man using semaglutide — or any aggressive caloric deficit strategy — is straightforward. Protein intake needs to be high, targeting at least 1.6 grams per kilogram of body weight daily, and ideally closer to 2.0 grams if you are lifting regularly. Resistance training should be performed at least three times per week, emphasizing compound movements that recruit large muscle groups. These are not optional lifestyle accessories. They are clinical necessities if you want the weight you lose to be predominantly fat rather than muscle.

Who Should Think Carefully Before Starting — and What Long-Term Really Means

Long-term safety also means confronting the reality that semaglutide is, for most people, a medication that needs to be taken indefinitely to maintain its effects. This is not a design flaw — it reflects the biological reality of obesity as a chronic, progressive, relapsing disease, a framing supported explicitly by the 2023 review in Diabetes, Obesity & Metabolism. When people discontinue semaglutide, a substantial proportion of lost weight returns within a year. This is not weakness or lack of willpower. It is pharmacology: the drug recalibrates appetite-regulating hormones and hypothalamic set points, and when the drug is removed, those systems revert.

That means a man who starts semaglutide at 42 may reasonably be taking it at 62. The SUSTAIN and STEP extension data cover periods up to two years with maintained efficacy and no emergent long-term safety signals, and the SELECT trial extended safety observation to over three years. But multi-decade data simply does not yet exist, because the drug has not been available that long. This is not a reason to panic — most widely used medications lack 30-year follow-up data at the time of approval — but it is a reason to make decisions with clear eyes and to stay engaged with the evolving evidence.

Men with a personal or family history of medullary thyroid carcinoma, MEN2, or a prior history of pancreatitis should not use semaglutide. Men with gastroparesis or severe gastrointestinal disease require careful evaluation before starting. Anyone considering GLP-1 therapy should have a prescribing clinician who is actively monitoring not just weight, but metabolic markers, kidney function, muscle mass where feasible, and nutritional status over time. The drug is not set-and-forget. Like any chronic medication, it requires ongoing clinical oversight.

It is also worth noting that semaglutide is not the only legitimate path to metabolic health. Men who achieve sustained fat loss and cardiovascular improvement through disciplined training, dialed-in nutrition, and lifestyle optimization are not missing out. The drug is a powerful tool for those who need it — particularly those with significant obesity-related comorbidities, or for whom conventional approaches have genuinely failed — but it is one tool in a broader framework, not a prerequisite for health.

What This Means For You

The current evidence supports semaglutide as a safe and effective long-term intervention for men with obesity, particularly those with cardiometabolic risk factors that lifestyle change alone has not adequately addressed. The AGA guideline, the cardiovascular outcomes data, and the growing body of real-world evidence all point in the same direction. The side effect profile is manageable for most users. The serious risks are real but uncommon, and well-characterized enough to screen for at the prescribing stage.

The most important thing the research has clarified in the past two years is not whether semaglutide works — that question is settled — but how to use it well. Prioritize protein. Train with weights. Work with a clinician who monitors your body composition alongside your body weight. Understand that this is a long-term commitment, not a 90-day reset. And recognize that the best version of long-term semaglutide use looks less like taking a weekly injection and more like building the kind of lifestyle infrastructure that compounds with the drug’s effects rather than depending on them entirely.